FIB-4 Index Calculator: First-Line Non-Invasive Liver Fibrosis Screening

Calculate the FIB-4 index using age, AST, ALT, and platelets to screen for advanced liver fibrosis (F3–F4) and cirrhosis in MASLD and viral hepatitis.

The Fibrosis-4 (FIB-4) index is the foremost non-invasive liver fibrosis score recommended by clinical practice guidelines from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL). Originally developed by Dr. Richard K. Sterling and colleagues in 2006 to evaluate hepatic fibrosis in HIV/HCV coinfected cohorts, the FIB-4 calculator has been rigorously validated worldwide as an accurate, cost-effective, first-line triage instrument in metabolic dysfunction-associated steatotic liver disease (MASLD / MASH), chronic hepatitis B, and chronic hepatitis C. Utilizing four readily available clinical variables—patient age, serum AST, serum ALT, and platelet count—FIB-4 stratifies individuals into low risk, indeterminate risk, and high risk of advanced fibrosis (METAVIR stage F3–F4) or cirrhosis, guiding specialty hepatology referrals and secondary elastography testing.

Clinical Need for Non-Invasive Fibrosis Assessment

With the global pandemic of obesity, type 2 diabetes, and metabolic syndrome, MASLD (formerly NAFLD) now affects over 30% of the global adult population. While simple hepatic steatosis carries relatively benign liver-specific mortality, progression to advanced fibrosis (bridging fibrosis, stage F3) and cirrhosis (stage F4) exponentially increases the risk of liver-related mortality, portal hypertension, and hepatocellular carcinoma.

Historically, liver biopsy was the gold standard for staging fibrosis. However, liver biopsy is invasive, expensive, carries procedural risks (bleeding, pain, perforation), and suffers from significant sampling error. The FIB-4 index provides a non-invasive, zero-cost screening tool that primary care physicians, endocrinologists, and gastroenterologists can calculate using routine blood tests during annual preventive health evaluations.

Mathematical Equation and Biomarker Rationale

The FIB-4 index integrates four routine parameters through a validated non-linear formula:

FIB-4 = (Age [years] × AST [U/L]) / (Platelet Count [10⁹/L] × √ALT [U/L])

The biological rationale behind each variable is physiologically grounded:

1. Patient Age: Hepatic fibrosis progression is strongly time-dependent, reflecting cumulative years of metabolic or viral parenchymal insult.

2. AST and ALT Ratio: In early liver injury, ALT typically exceeds AST. As progressive sinusoidal fibrosis and architectural remodeling advance, hepatic clearance of AST decreases and mitochondrial injury escalates, causing AST to rise above ALT (AST/ALT ratio > 1.0).

3. Platelet Count: Progressive portal hypertension causes splenomegaly, resulting in splenic sequestration and destruction of circulating platelets. Concurrently, cirrhotic hepatocytes decrease production of thrombopoietin (TPO). Consequently, declining platelet count is a sensitive surrogate for advancing fibrosis and portal hypertension.

Validated Diagnostic Cutoffs and Clinical Action Algorithms

AASLD practice guidelines establish structured risk tiers and clinical referral algorithms based on the calculated FIB-4 score:

• Low Risk (FIB-4 < 1.30; < 2.0 in adults aged ≥ 65): Possesses a high negative predictive value (>90% to 95%) for ruling out advanced fibrosis (F3–F4). Patients in this category can be managed safely in primary care with lifestyle interventions and re-screened in 1 to 2 years.

• Indeterminate Zone (FIB-4 1.30 to 2.67): Represents diagnostic uncertainty. Guidelines recommend reflex secondary testing, typically vibration-controlled transient elastography (VCTE / FibroScan) or the Enhanced Liver Fibrosis (ELF) test to clarify fibrosis risk.

• High Risk (FIB-4 > 2.67): Possesses a high positive predictive value for advanced fibrosis or cirrhosis. Patients should be referred promptly to a gastroenterologist or hepatologist for comprehensive staging, HCC ultrasound surveillance, and variceal screening.

Relationship Between FIB-4 and the Child-Pugh Score

Understanding the clinical continuum between FIB-4 and Child-Pugh is essential. The FIB-4 index is an outpatient screening tool designed to detect fibrosis and occult cirrhosis in asymptomatic individuals before clinical decompensation occurs. Once a patient develops established cirrhosis (F4) and experiences clinical complications (ascites, jaundice, coagulopathy), the child pugh score calculator and MELD 3.0 take over as the definitive staging tools to guide functional reserve and perioperative survival.

Clinical takeaways

  • FIB-4 = (Age × AST) / (Platelets × √ALT).
  • Cutoffs: <1.30 (low risk, rule-out); 1.30–2.67 (indeterminate, get FibroScan); >2.67 (high risk, refer to hepatology).
  • Age-adjusted cutoff for age ≥65 is <2.0 for low risk.

Limitations

  • Age dependence: High false-positive rates in patients aged ≥65 years unless age-adjusted cutoffs (<2.0) are applied.
  • Less accurate in patients under 35 years of age.
  • Acute hepatocellular injury (acute alcohol flare, acute viral hepatitis) falsely inflates AST and FIB-4.

References

  1. Sterling RK, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325.
  2. Rinella ME, et al. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology. 2023;77(5):1797-1835.